EQUITY $ 17,307 $ 19,185
========= ======= =========
(* Represents an amount lower than $1 USD.)
NUVECTIS PHARMA, INC.
CONDENSED STATEMENTS OF OPERATIONS
(USD in thousands, except per share and share amounts)
(unaudited)
Three Months Ended Nine Months Ended September
September 30 30
-------------------------- ----------------------------
2024 2023 2024 2023
----------- ----------- ----------- -----------
OPERATING
EXPENSES:
Research and
development $ 2,819 $ 4,486 $ 8,422 $ 11,115
General and
administrative 1,540 1,672 4,976 4,916
---------- ---------- ---------- ----------
OPERATING LOSS (4,359) (6,158) (13,398) (16,031)
---------- ---------- ---------- ----------
Finance income 206 277 646 393
---------- ---------- ---------- ----------
NET LOSS $ (4,153) $ (5,881) $ (12,752) $ (15,638)
========== ========== ========== ==========
NET LOSS
ATTRIBUTABLE TO
COMMON
STOCKHOLDERS $ (4,153) $ (5,881) $ (12,752) $ (15,638)
---------- ---------- ---------- ----------
BASIC AND DILUTED
NET LOSS PER
COMMON STOCK
OUTSTANDING $ (0.24) $ (0.37) $ (0.75) $ (1.02)
========== ========== ========== ==========
Basic and diluted
weighted average
number of common
stock
outstanding 17,230,559 16,104,446 16,898,040 15,341,685
========== ========== ========== ==========
(END) Dow Jones Newswires
November 05, 2024 07:00 ET (12:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.